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Abstract. Despite recent advances, the prognosis of relapsed
osteosarcoma patients remains very poor. Application of high
energy shock waves may change the tumour cell growth and
increase the cytotoxic effect of in vivo and in vitro chemo-
therapeutic agents. We studied the effect of their association
with doxorubicin or methotrexate on three in vitro osteo-
sarcoma cell lines. The effect of these combinations on
SJSA-1, MG-63 and HOS human osteosarcoma cell lines
were evaluated through incubation with doxorubicin or
methotrexate and high energy shock wave treatment with
1000 shots at 0.22 mJ/mm2 and an evaluation of the cell
number, cell proliferation and apoptosis at days 1, 3 and 6
from the start of treatment. The combination of high energy
shock waves and doxorubicin induced a statistically significant
advantage in terms of a decrease in cell number on the SJSA-1
and HOS cell lines, a decrease of cell proliferation on all
three cell lines and an increase of apoptosis only on the
SJSA-1 cell line. The combination of high energy shock
waves with methotrexate induced a decrease of the cell
number only in the SJSA-1 and in the HOS cell lines, of the
cell proliferation in the SJSA-1 and in the MG-63 cell lines,
and an increase of apoptosis only on the SJSA-1 cell line. In
conclusion, these experiments show an interesting effect of
high energy shock waves on osteosarcoma cell lines, which
could lead to future studies of the in vivo effects of high
energy shock waves in the murine model as well.
Introduction
Osteosarcoma (OS) is the most frequent bone tumour and is
most common between the ages of 15 and 25. A high number
of patients have a high-grade tumour, which prognosis has
dramatically improved from 10-15% to 65-70% in the last
25 years, thanks to the use of adjuvant and neoadjuvant
chemotherapy (1,2). Nevertheless, despite continuing scientific
research into the treatment, the prognosis of the patients with
OS in metastatic relapse, especially to bones (3), is still very
poor; even with a recently concluded Italian and Scandinavian
phase II protocol including high-dose chemotherapy the 3-year
overall survival and the 3-year disease free-survival rates were
only 20% and 12% respectively (4).
The search of new treatments for improving the survival
of the patients without increasing the collateral effects of the
chemotherapy has led us to study new ways to increase the
chemo-sensitivity of the OS cells.
High energy shock waves (HESW) are routinely used in
clinical practise in orthopaedic and in urology to treat a number
of different diseases, such as urinary stones, non-unions of
the bone fractures, tennis elbow, calcifying tendonitis, pseudo-
arthrosis and necrosis of the femoral head (5,6).
In the past, many studies of HESW were conducted on
different human and animal tumour cell lines, describing an
alteration of the cell growth (7-11). The in vitro effects of
shock waves are due to a suppression of cell proliferation
correlated with an apoptotic cell death process; moreover,
HESW treatment has been shown to cause a transient increase
in cell membrane permeability by opening micropores (such
as electroporation), allowing higher intracellular drug con-
centration (12-16). This effect has been shown as being capable
of increasing the cytotoxicity of various chemotherapeutic
agents on different tumour types, allowing treatments with
lower doses of drugs in vitro (17-19), in vivo in animal models
(12,20) and in one patient with prostate cancer (21).
This evidence led us to study the effects of HESW on OS
cell lines and how to enhance cytotoxicity with a combined
therapy with HESW and doxorubicin (DOXO) or methotrexate
(MTX). These cytotoxic agents have been chosen since their
well-known activity against OS and their routine use in clinical
protocols for the treatment of OS patients (22-27).
Here, we show how HESW treatment enhances the cyto-
toxicity of two drugs against three OS cell lines by reducing
cell viability and cell proliferation and by increasing the
apoptosis levels.
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Materials and methods
Cell cultures. We analyzed three human OS cell lines: SJSA-1,
MG-63 and HOS, obtained from the American Type Culture
Collection. The SJSA-1 cell line was maintained in Roswell
Park Memorial Institute Medium (RPMI, Sigma), while MG-63
and HOS cell lines were maintained in Eagle's minimum
essential medium (EMEM, EuroClone), both supplemented
with 10% foetal bovine serum (FBS) and 0.5 mg/ml penicillin/
streptomycin. Once a week, cells were detached with trypsin/
EDTA (Cambrex, Verviers, Belgium), counted and re-seeded
at 1x106 cell/flask.
Shock wave exposure. The shock wave generator used for the
in vitro experiments is a piezoelectric device (Piezoson 100,
Richard Wolf, Knittlingen, Germany) especially designed
for clinical use in orthopaedics and traumatology. The
instrument, kindly provided by Med & Sport 2000 S.r.l., Turin,
Italy, generates focused underwater shock waves at various
frequencies (1-4 shocks/sec) and intensities (0.05-1.48 mJ/
mm2). The device has a high voltage electric current generator
and a reflector set in a water-filled container. On the surface
of the reflector, piezoelectric elements arranged to form a
part of a sphere, are stimulated with high energy electrical
pulses. This causes vibration or the rapid expansion of the
crystals, leading to a shock wave, which can be propagated
through the water and focused at the centre of the sphere.
The pressure on the focal area is proportional to the voltage
applied. The energy at the focal point is defined as the energy
flux density (EFD) per impulse (28), recorded as joules per
area (mJ/mm2). For medical use, in orthopaedics, shock waves
of approximately 0.01-0.6 mJ/mm2 are applied (29). The focal
area, which is peculiar to each kind of generator, is defined
as the area in which 50% of the maximum energy is reached
(30): with regard to Piezoson 100, it has a length of 10 mm in
the direction of the axis of the shock wave and a diameter of
2.5 mm perpendicular to this axis.
Aliquots 1 ml of cell suspension adjusted to 5x106 cell/ml
in of medium were placed into 2 ml polypropylene tubes
(Corning, New York, NY, USA), which were then completely
filled with culture medium. Then, cells were slowly pelletted
by centrifugation at 250 x g in order to minimize the motion
during shock wave treatment.
The experimental set-up was performed as previously
described (17). Briefly, each tube was placed in vertical
alignment with the focal area and was adjusted so that the
central point of the focal area corresponded to the centre of
the tube bottom. The shock wave unit was kept in contact
with the cell containing tube by means of a water-filled
cushion. Common ultrasound gel was used as a contact
medium between the cushion and the tube. Cells were treated
as follows: control cells received no shock wave treatment,
while treated cells received 1000 shots (frequency: 4 shocks/
sec) at EFD = 0.22 mJ/mm2 (E0.22-1000) (peak positive
pressure 31 MPa; peak negative pressure 4.3 MPa). Each
experiment was carried out in independent triplicate of three
separate experiments.
Drug treatment. After shock wave treatment, treated and
untreated cells were seeded in triplicate in complete medium
in 96-multi-well plates (Greiner Bio-One, Longwood, FL,
USA) for the cell proliferation test, or in 6-well plates
(Greiner Bio-One, Longwood, FL, USA) for cell viability
and apoptosis evaluations in absence or presence of 0.1 μM
DOXO (Pharmacia Italia S.p.a., Milan, Italy) or 0.03 μM
MTX (Teva Pharma B.V., Mijdrecht, The Netherlands).
Each experiment was set up in triplicate of three separate
experiments.
Cell viability. Before and after HESW treatment, cell viability
was assayed with trypan blue dye exclusion. On day 0,
treated and untreated cells were plated in triplicates in 6-well
plates at 0.5x106 cells/well (for the days 1 and 3 evaluations)
or at 0.15x106 cells/well (for the day 6 evaluation), and
then incubated at 37˚C in 5% CO2. At days 1, 3 and 6 after
treatment, cells were detached with trypsin/EDTA and viable
cell growth was determined by a microscopy count with trypan
blue dye exclusion (3 counts for each sample).
Cell proliferation. On day 0, treated and untreated cells were
plated in triplicates in 96-well plates at 5x103 cells/well (for
the days 1 and 3 evaluations) or at 2.5x103 cells/well (for the
day 6 evaluation), then incubated at 37˚C in 5% CO2 till days
1, 3 and 6 after treatment. All conditions were set up in
triplicate. Then cells were pulsed with 0.5 μCi/well of [3H]-
thymidine (Amersham Bioscienses, Buckinghamshire, UK) for
18 h and then frozen. The day after, the plates were defrosted
to detach adherent cells and then cells were harvested using a
micro cell harvester (Filtermate harvester, Packard, Perkin
Elmer, Boston, MA, USA) and counted with a Beta-counter
(RackBeta 1219, Wallac, Evry, France). Percentage specific
inhibition was calculated by the formula (CPM, counts per
minute):
Sample CPM
% inhibition = ––––––––––––  x 100
Control CPM
Apoptosis determination. On day 0, treated and untreated
cells were plated in triplicate in 6-well plates at 0.5x106 cells/
well (for days 1 and 3 evaluations) or at 0.15x106 cells/well
(for the day 6 evaluation), and then incubated at 37˚C in 5%
CO2. At days 1, 3 and 6 after treatment the cells were detached
with trypsin/EDTA and analysed with FACScan cytometer
(Beckman Coulter, Fullerton, CA) using the Annexin V-
fluorescein isothiocyanate (FITC) Apoptosis Detection Kit 1
(BD PharMingen, San Diego, CA). In brief, at least 2x105 cells
were washed with phosphate buffer saline (PBS, Cambrex
Bioscience, Verviers, Belgium), incubated for 15 min at room
temperature in 100 μl of Annexin binding buffer with 5 μl of
Annexin V and 5 μl of propidium iodide (PI) staining solution
and then, after the addition of 300 μl of Annexin binding
buffer, analyzed by flow cytometry within 30 min.
Statistical analysis. Each condition was carried out in three
independent experiments. Data were expressed as means ±
standard deviation (SD) for each group. Data were analyzed
for statistical significance between each condition and their
controls using the two-sided Student's t-test; statistical
significance was set at p<0.05.
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Results
Preliminary experiments were carried out to set up the optimal
experimental conditions. E0.22-1000 were chosen after all
the cell lines had been treated with different combinations
of 300, 500, 1000 or 1500 shots at 0.15, 0.22, 0.32, 0.43 or
0.88 mJ/mm2 (peak positive pressure respectively at 26, 31,
38, 50 and 90 MPa) and evaluated for cell viability and cell
apoptosis: a cell exposure up to 1000 shots at 0.22 mJ/mm2
left enough viable cells for further drug treatments in all three
evaluated cell lines. A higher number of shots (1500) decreased
the cell viability with respect to untreated cells, while a smaller
number of shots (500) was almost ineffective as treatment,
even with an higher energy such as 0.88 mJ/mm2. A low
viability was also obtained with a combination of higher
energies and 1000 shots. For all three lines we performed all
the different combinations (Fig. 1).
DOXO concentrations of 0.1 μM for SJSA-1 and of
0.01 μM for MG-63 and HOS were chosen after in vitro
examinations of cell viability and cell apoptosis after 1, 3 and
6 days of culture with different drug concentrations (0.01,
0.05, 0.1, 1 and 10 μM), showing a different sensitivity
between the three cell lines: lower concentrations were not
tried since previous studies have shown the efficacy of
DOXO on OS cell lines to be around 0.02-0.6 μM (31,32). In
our experiments, higher concentrations of those chosen were
too toxic for the cells (Fig. 2).
MTX concentration of 0.03 μM for all the three lines was
chosen after in vitro examinations of cell viability and cell
apoptosis after 1, 3 and 6 days culture with different drug
concentrations (0.0003, 0.003 and 0.03 μM). As described
elsewhere, OS cell lines have a different sensitivity to MTX:
MG-63 and HOS cell lines are among the most responsive to
this drug, even at a very low concentration such as 0.01 μM
(33). In our preliminary experiments, concentrations lower
than 0.03 μM proved inefficient, while a higher concentration
was too toxic and did not leave enough viable cells for the
evaluation of the HESW treatment (Fig. 3).
For all the experiments, combined treatment (HESW-
DOXO cells or HESW-MTX cells) was compared with
controls (untreated cells, DOXO cells, MTX cells or HESW
cells). Data are expressed as mean of three values.
SJSA-1 cell line (Figs. 4 and 5)
Cell viability. HESW alone significantly reduced cell
viability of 40.5% (p=0.00004), 64% (p=0.00003) and 53.5%
(p=0.0000008) at days 1, 3 and 6 in comparison to untreated
cells. With the HESW-DOXO cells we had a reduction of the
cell viability at days 1 [of 17%, p-value not significant (NS)]
and 3 (of 29%, p=0.02) in comparison to the drug alone, while
at day 6 all the cells were dead. With the HESW-MTX cells
we obtained a statistically significant reduction of the cell
viability of 40% (p=0.03), 31% (p=0.05) and 52% (p=0.03)
at days 1, 3 and 6 in comparison with the MTX alone.
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Figure 1. The effect of a different combination of energies and number of
shots of HESWs on the cell number of SJSA-1 (A), MG-63 (B) and HOS
cell lines (C).
Figure 2. The effect of different concentrations of DOXO on the cell numbers
of SJSA-1 (A), MG-63 (B) and HOS cell lines (C).
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Cell proliferation. The effect of HESW on the cell pro-
liferation is shown by a reduction of 48% (p=0.00006), 71%
(p=0.000003) and 53.5% (p=0.003) at days 1, 3 and 6,
respectively, compared to untreated cells. As for the cell
number, the combination of HESW and DOXO caused a
decrease of 42% (p=0.008), 43% (p=0.02) and 3% (p=0.03)
at days 1, 3 and 6 compared to DOXO cells. Also the
association HESW and MTX caused a reduction of 63%
(p=0.01), 36% (p=0.049) and 55% (p=0.03) at days 1, 3 and
6 in comparison to MTX-cells.
Apoptosis determination. HESW gave rise to an increase of
3.5- (p=0001), 1.9- (p=0.005) and 1.3-fold (p=NS) of Annexin
positive (+) cells and of 8.8- (p=0.00002), 3.5- (p=0.0002)
and 1.2-fold (p=NS) of PI+ cells at days 1, 3 and 6. With the
HESW-DOXO cells we saw an increase of the Annexin+ cells
of 2.1- (p=0.0004), 1.7- (p=NS) and 1.1-fold (p=NS); also
the PI+ cells increased of 6.7- (p=0.0008), 5.7- (p=0.03) and
1.6-folds (p=NS) at days 1, 3 and 6 compared to DOXO-
cells. In the HESW-MTX cells we obtained an increase of 8.2-
(p=0.04), 0.4- (p=NS) and 9.6-fold (p=0.01) of the Annexin+
cells and of 22.8- (p=0.04), 2.5- (p=NS) and 11.7-fold
(p=0.02) of the PI+ cells at days 1, 3 and 6 compared to MTX
cells.
MG-63 cell line (Figs. 6 and 7)
Cell viability. HESW had a small effect on the MG-63 cell
line, causing a reduction of the cell number of 26% (p=0.0005),
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Figure 4. Effect of the association of HESW and DOXO on SJSA-1 cell line
on cell number (A), cell proliferation (B) and apoptosis (C).
Figure 5. Effect of the association of HESW and MTX on SJSA-1 cell line
on cell number (A), cell proliferation (B) and apoptosis (C).
Figure 3. The effect of different concentrations of MTX on the cell numbers
of SJSA-1 (A), MG-63 (B) and HOS cell lines (C).
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15.5% (p=NS) and 13% (p=NS) at days 1, 3 and 6. When the
HESW and DOXO combination was applied, no enhanced
toxicity was found compared to DOXO cells. The combination
HESW and MTX caused an increase of the effect of the 15%
(p=NS) at day 1, 22% (p=0.02) at day 3 and 9% (p=NS) at day
6, in comparison to MTX cells.
Cell proliferation. As regards to the cell proliferation, HESW
caused a reduction of 37% (p=0.0004) at day 1, of 32.5%
(p=0.00007) at day 3 and of 13.5% (p=NS) at day 6. The cell
proliferation of the HESW-DOXO cells decreased by 44%
(p=0.002), 10% (p=NS) and 3% (p=NS) at days 1, 3 and 6 in
comparison to DOXO cells. The HESW-MTX combination
did not decrease the cell proliferation at any time and may be
compared to MTX cells.
Apoptosis determination. HESW alone caused an Annexin+
cell increase at days 1, 3 and 6 of 1.7- (p=NS), 1.2- (p=NS)
and 1.1-fold (p=NS) respectively, and a PI+ cell increase of
1.8- (p=NS), 1.2- (p=NS) and 1.1-fold (p=NS), compared to
untreated cells. With HESW-DOXO cells we did not obtain a
statistically significant increase of the Annexin and PI
positivity. With the MTX addition we achieved only a
significant PI+ cell increase of 2.5-fold (p=0.008) at day 1.
HOS cell line (Figs. 8 and 9)
Cell viability. HESW treatment alone induced a cell number
reduction at day 1 of 18% (p=0.004), at day 3 of 19.5%
(p=0.02) and at day 6 of 22% (p=NS) in comparison to the
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Figure 6. Effect of the association of HESW and DOXO on MG-63 cell line
on cell number (A), cell proliferation (B) and apoptosis (C).
Figure 7. Effect of the association of HESW and MTX on MG-63 cell line
on cell number (A), cell proliferation (B) and apoptosis (C).
Figure 8. Effect of the association of HESW and DOXO on HOS cell line on
cell number (A), cell proliferation (B) and apoptosis (C).
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untreated cells. The combination of HESW and DOXO caused
a cell number reduction of 30% (p=0.005) and 21% (p=0.02)
at days 1 and 3; at day 6, all the cell were already dead even
with DOXO alone. With the HESW-MTX cells we obtained
a cell number reduction of 22% (p=NS) at day 1 and of 2%
(p=NS) at day 3; no viable cells were found in any wells at
day 6.
Cell proliferation. An analysis of cell proliferation showed
the same trend: HESW alone caused a decrease of 19.5%,
17% and 0% at days 1, 3 and 6 respectively, compared to
untreated cells. The HESW-DOXO combination decreased
the cell proliferation by 32% (p=0.02), 19% (p=0.02) and 5%
(p=NS) at days 1, 3 and 6 compared to DOXO cells, while
the HESW-MTX combination did not decrease the cell
proliferation compared to MTX cells.
Apoptosis determination. HESW alone did not have an effect
on the Annexin and PI positivity; neither did the addition of
DOXO and MTX.
Discussion
Patients affected by relapsed OS have a very poor prognosis.
To improve the chemo-sensitivity of OS cells, the effects of
HESW have been evaluated. In this series of experiments we
show how the HESW treatment seems to have a beneficial
role on the enhancement of drug cytotoxicity. Three major
points have been evaluated in this study.
The first was aimed at the study of the cell viability
reduction following HESW treatment. In the SJSA-1 cell line
the greatest effect was on day 3 from the start of treatment
with HESW-DOXO treatment and on day 6 with HESW-
MTX treatment. Cell viability difference (between drug-
treated cell and HESW-drug-treated cells) increased for
DOXO from 17% at day 1 to 29% on day 3, but the effect
was annulled on day 6. However, when we compared the cell
viability following MTX treatment, the difference was 40%
at day 1, of 31% at day 3 and 52% at day 6. This may be due
to different mechanisms of cytotoxicity of the two drugs.
With the MG-63 cell line, we observed that both DOXO and
MTX are slightly efficacious at days 1, 3 and 6. For the HOS
cell line, the increase of efficacy with the combined
treatment of HESW and drugs is evident on days 1 and 3 for
DOXO but only on day 1 for MTX; then the effect is
annulled by the high cell mortality given by the drugs alone.
These differences might be due to a different sensitivity or
resistance of the different OS cell lines to the same cytotoxic
agent.
The second point was the cell proliferation, measured by
the [3H]-thymidine assay. In all three OS cell lines evaluated,
we found that the addition of HESW to DOXO enhanced
the reduction of cell proliferation from day 1 to day 6. This
was not confirmed with the combination of HESW and
MTX, where the MG-63 cell line had a reduction in the cell
proliferation only on days 1 and 3 and the HOS cell line
seemed unaffected by the HESW treatment.
The third point evaluated was on the pro-apoptotic effect
of the HESW treatment. In these series of experiments, a
significant increase of apoptosis was documented with the
addition of the HESW to the DOXO or MTX only on the
SJSA-1 cell line. The data might be due to a necrotic death of
cells due to the opening of micropores in the cell membranes,
producing higher drug concentration in cells.
Taken together the data open new perspectives for the
study of both the biological properties of OS cells and for the
future in vivo applications, especially in localized OS patients
in whom the increasing of drug concentration might increase
the necrotic cell death by the local administration of the
drugs.
These data are promising for a better understanding of the
optimal treatment for advanced or resistant OS tumours, but
future work, including in vivo mouse experiments, needs to be
carried out before further conclusions can be made.
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